High-throughput homogeneous immunoassay readily identifies monoclonal antibody to serovariant clostridial neurotoxins

Journal of Immunological Methods

Volumn 328, Issue 1-2, 2007, Pages 128-138

  Corbett, Cindi R ^a,b   Elias, Mohammad D ^c   Simpson, Lance L ^c   Yuan, Xin Yong ^a   Cassan, Robyn R ^d   Ballegeer, Erin ^a   Kabani, Amin ^a,b   Plummer, Francis A ^a,b   Berry, Jody D ^a,b  

^a PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d CANADIAN FOOD INSPECTION AGENCY   (Canada)

Author keywords

Clostridium neutrotoxins; High throughput screening; Monoclonal antibody

Indexed keywords

AGAROSE; BOTULINUM TOXIN A; BOTULINUM TOXIN B; BOTULINUM TOXIN E; CLOSTRIDIUM TOXIN; MONOCLONAL ANTIBODY;

ANTIBODY DETECTION; ANTIBODY SPECIFICITY; ARTICLE; CELL SURFACE; CLOSTRIDIUM BOTULINUM; CROSS REACTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUOROMETRY; HIGH THROUGHPUT SCREENING; HYBRIDOMA; IMMUNOASSAY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; BOTULINUM TOXINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HYBRIDOMAS; IMMUNOASSAY; MICE; MICE, INBRED BALB C; NEUROTOXINS;

CLOSTRIDIUM; CLOSTRIDIUM BOTULINUM;

EID: 35548954573     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jim.2007.08.017     Document Type: Article

References (25)

1. Arnon S.S., Schechter R., Inglesby T.V., Henderson D.A., Bartlett J.G., Ascher M.S., Eitzen E., Fine A.D., Hauer J., Layton M., Lillibridge S., Osterholm M.T., O'Toole T., Parker G., Perl T.M., Russell P.K., Swerdlow D.L., and Tonat K. Botulinum toxin as a biological weapon: medical and public health management. JAMA 285 8 (2001) 1059 (2-28)
2. Arnon S.S., Schechter R., Maslanka S.E., Jewell N.P., and Hatheway C.L. Human botulism immune globulin for the treatment of infant botulism. N. Engl. J. Med. 354 5 (2006) 462 (2-2)
3. Baldwin M.R., Tepp W.H., Pier C.L., Bradshaw M., Ho M., Wilson B.A., Fritz R.B., Johnson E.A., and Barbieri J.T. Characterization of the antibody response to the receptor binding domain of botulinum neurotoxin serotypes A and E. Infect. Immun. 73 10 (2005) 6998
4. Berry J.D. Rational monoclonal antibody development to emerging pathogens, biothreat agents and agents of foreign animal disease: the antigen scale. Vet. J. 170 2 (2005) 193
5. Berry J.D., Peeling R.W., and Brunham R.C. Analysis of the original antigenic sin antibody response to the major outer membrane protein of Chlamydia trachomatis. J. Infect. Dis. 179 1 (1999) 180
6. Berry J.D., Jones S., Drebot M.A., Andonov A., Sabara M., Yuan X.Y., Weingartl H., Fernando L., Marszal P., Gren J., Nicolas B., Andonova M., Ranada F., Gubbins M.J., Ball T.B., Kitching P., Li Y., Kabani A., and Plummer F. Development and characterisation of neutralising monoclonal antibody to the SARS-coronavirus. J. Virol. Methods 120 1 (2004) 87 (9-1)
7. Boles J., West M., Montgomery V., Tammariello R., Pitt M.L., Gibbs P., Smith L., and LeClaire R.D. Recombinant C fragment of botulinum neurotoxin B serotype (rBoNTB (HC)) immune response and protection in the rhesus monkey. Toxicon 47 8 (2006) 877 (6-15)
8. Chai Q., Arndt J.W., Dong M., Tepp W.H., Johnson E.A., Chapman E.R., and Stevens R.C. Structural basis of cell surface receptor recognition by botulinum neurotoxin B. Nature 444 7122 (2006) 1096 (12-21)
9. Dertzbaugh M.T., and West M.W. Mapping of protective and cross-reactive domains of the type A neurotoxin of Clostridium botulinum. Vaccine 14 16 (1996) 1538
10. Edl J., Mernaugh R., and Wright D.W. Assays for selection of single-chain fragment variable recombinant antibodies to metal nanoclusters. Methods Mol. Biol. 303 (2005) 113
11. Fazekas de, St Groth, and Webster R.G. Disquisitions of original antigenic Sin.I. Evidence in man. J. Exp. Med. 124 3 (1966) 331 (9-1)
12. Gill D.M. Bacterial toxins: a table of lethal amounts. Microbiol. Rev. 46 1 (1982) 86
13. Hallborn J., and Carlsson R. Automated screening procedure for high-throughput generation of antibody fragments. Biotechniques (2002) 30 (Suppl)
14. Komatsu N., Shichijo S., Maeda Y., and Itoh K. Measurement of interferon-gamma by high-throughput fluorometric microvolume assay technology system. J. Immunol. Methods 263 1-2 (2002) 169 (5-1)
15. Miller D.K., Menke J.D., Hayes N.S., Uzieblo A., Tew D., Hayashi Y., Guan Y., Zhao A., Cummings R.T., Park Y.W., and Yamin T.T. Development of a high-capacity homogeneous fluorescent assay for the measurement of leukotriene B4. Anal. Biochem. 349 1 (2006) 129 (2-1)
16. Miraglia S., Swartzman E.E., Mellentin-Michelotti J., Evangelista L., Smith C., Gunawan I I., Lohman K., Goldberg E.M., Manian B., and Yuan P.M. Homogeneous cell- and bead-based assays for high throughput screening using fluorometric microvolume assay technology. J. Biomol. Screen. 4 4 (1999) 193
17. Nowakowski A., Wang C., Powers D.B., Amersdorfer P., Smith T.J., Montgomery V.A., Sheridan R., Blake R., Smith L.A., and Marks J.D. Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proc. Natl. Acad. Sci. U. S. A. 99 17 (2002) 11346 (8-20)
18. Pless D.D., Torres E.R., Reinke E.K., and Bavari S. High-affinity, protective antibodies to the binding domain of botulinum neurotoxin type A. Infect. Immun. 69 1 (2001) 570
19. Popoff M.R. Ecology of neurotoxigenic strains of clostridia. Curr. Top. Microbiol. Immunol. 195 (1995) 1
20. Ravichandran, E., Al-Saleem, F.H., Ancharski, D.M., Elias, M., Singh, A.K., Shamim, M., Gong, Y., and Simpson, L.L., 2007. A trivalent vaccine against botulinum toxin serotypes A, B and E that can be administered by the mucosal route. Infect. Immun. 75 (6), 3043.
21. Smith T.J., Lou J., Geren I.N., Forsyth C.M., Tsai R., Laporte S.L., Tepp W.H., Bradshaw M., Johnson E.A., Smith L.A., and Marks J.D. Sequence variation within botulinum neurotoxin serotypes impacts antibody binding and neutralization. Infect. Immun. 73 9 (2005) 5450
22. Swartzman E.E., Miraglia S.J., Mellentin-Michelotti J., Evangelista L., and Yuan P.M. A homogeneous and multiplexed immunoassay for high-throughput screening using fluorometric microvolume assay technology. Anal. Biochem. 271 2 (1999) 143 (7-1)
23. Toney J.H., Ogawa A., Blair M., and Park Y.W. A "mix and read" assay for insulin using fluorometric microvolume assay technology. Assay. Drug Dev. Technol. 1 4 (2003) 521
24. Wictome M., and Shone C.C. Botulinum neurotoxins: mode of action and detection. Symp. Ser. Soc. Appl. Microbiol. 27 (1998) 87S
25. Zhang Y., Pool C., Sadler K., Yan H.P., Edl J., Wang X., Boyd J.G., and Tam J.P. Selection of active ScFv to G-protein-coupled receptor CCR5 using surface antigen-mimicking peptides. Biochemistry 43 39 (2004) 12575 (10-5)